scholarly journals Synthesis of HIV-1 capsid protein assembly inhibitor (CAP-1) and its analogues based on a biomass approach

2016 ◽  
Vol 14 (45) ◽  
pp. 10593-10598 ◽  
Author(s):  
Leonid V. Romashov ◽  
Valentine P. Ananikov
Keyword(s):  
Capsid Protein ◽  
Organic Synthesis ◽  
Low Cost ◽  
Protein Assembly ◽  
Pharmaceutical Substance ◽  
Platform Chemical ◽  
Anti Hiv ◽  
Hiv 1

The potential of a biomass-derived platform chemical is explored in the low cost sustainable organic synthesis of an anti-HIV pharmaceutical substance with flexible and variable units.

Anti-HIV-1 Activity of pepRF1, a Proteolysis-Resistant CXCR4 Antagonist Derived from Dengue Virus Capsid Protein

2020 ◽  
Author(s):  
Iris Cadima-Couto ◽  
Alexandra Tauzin ◽  
João M. Freire ◽  
Tiago N. Figueira ◽  
Rúben D. M. Silva ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Capsid Protein ◽  
Cxcr4 Antagonist ◽  
Virus Capsid ◽  
Anti Hiv ◽  
Virus Capsid Protein ◽  
Hiv 1

Latex bead immobilisation in PDMS matrix for the detection of p53 gene point mutation and anti-HIV-1 capsid protein antibodies

2004 ◽  
Vol 381 (5) ◽  
pp. 1019-1024 ◽  
Author(s):  
Christophe A. Marquette ◽  
Agn�s Degiuli ◽  
Emmanuelle Imbert-Laurenceau ◽  
Francois Mallet ◽  
Carole Chaix ◽  
...  
Keyword(s):  
Capsid Protein ◽  
Point Mutation ◽  
P53 Gene ◽  
Latex Bead ◽  
Anti Hiv ◽  
Hiv 1

scholarly journals Enhanced Neutralization of HIV by Antibodies Displayed on the S-Layer of Caulobacter crescentus

2011 ◽  
Vol 55 (12) ◽  
pp. 5547-5552 ◽  
Author(s):  
Mark Duval ◽  
Christopher J. Lewis ◽  
John F. Nomellini ◽  
Marc S. Horwitz ◽  
John Smit ◽  
...  
Keyword(s):  
Nonhuman Primates ◽  
Caulobacter Crescentus ◽  
Low Cost ◽  
Content Type ◽  
Innovative Methods ◽  
Hiv Antibodies ◽  
The Cost ◽  
Anti Hiv Agents ◽  
Anti Hiv ◽  
Hiv 1

ABSTRACTInnovative methods of prevention are needed to stop the more than two million new HIV-1 infections annually, particularly in women. Local application of anti-HIV antibodies has been shown to be effective at preventing infection in nonhuman primates; however, the concentrations needed are cost prohibitive. Display of antibodies on a particulate platform will likely prolong effectiveness of these anti-HIV agents and lower the cost of goods. Here, we demonstrate that the bacteriumCaulobacter crescentusand its highly expressed surface-layer (S-layer) protein can provide this antibody display platform. Caulobacters displaying protein G, alone or with CD4 codisplay, successfully captured HIV-1-specific antibodies and demonstrated functional neutralization. Compared to soluble antibodies, a neutralizing anti-HIV antibody displayed onCaulobacterwas as effective or more effective at neutralizing diverse HIV-1 isolates. Moreover, when an antibody reactive with an epitope induced by CD4 binding (CD4i) was codisplayed with CD4, there was significant enhancement in HIV-1 neutralization. These results suggest that caulobacters displaying anti-HIV antibodies offer a distinct improvement in the use of antibodies as microbicides. Furthermore, these reagents can specifically evaluate anti-HIV antibodies in concert with other HIV-1 blocking agents to assess the most suitable tools for conversion to scFvs, allowing for direct display within the S-layer protein and further reducing cost of goods. In summary,C. crescentus, which can be easily produced and chemically stabilized at low cost, is well suited for engineering as an effective platform, offering an inexpensive way to produce and deliver HIV-1-specific microbicides.

Identification of Novel Interactions in HIV-1 Capsid Protein Assembly by High-resolution Mass Spectrometry

2003 ◽  
Vol 325 (4) ◽  
pp. 759-772 ◽  
Author(s):  
Jason Lanman ◽  
TuKiet T. Lam ◽  
Stephen Barnes ◽  
Michael Sakalian ◽  
Mark R. Emmett ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
High Resolution ◽  
Capsid Protein ◽  
High Resolution Mass Spectrometry ◽  
Protein Assembly ◽  
High Resolution Mass ◽  
Novel Interactions ◽  
Hiv 1 ◽  
Resolution Mass

scholarly journals Ultra-low HIV-1 p24 detection limits with a bioelectronic sensor

2019 ◽  
Vol 412 (4) ◽  
pp. 811-818 ◽  
Author(s):  
Eleonora Macchia ◽  
Lucia Sarcina ◽  
Rosaria Anna Picca ◽  
Kyriaki Manoli ◽  
Cinzia Di Franco ◽  
...  
Keyword(s):  
Capsid Protein ◽  
Single Molecule ◽  
Limit Of Detection ◽  
Point Of Care ◽  
Low Cost ◽  
Wide Field ◽  
Label Free ◽  
Limit Of Quantification ◽  
Great Relevance ◽  
Hiv 1

AbstractEarly diagnosis of the infection caused by human immunodeficiency virus type-1 (HIV-1) is vital to achieve efficient therapeutic treatment and limit the disease spreading when the viremia is at its highest level. To this end, a point-of-care HIV-1 detection carried out with label-free, low-cost, and ultra-sensitive screening technologies would be of great relevance. Herein, a label-free single molecule detection of HIV-1 p24 capsid protein with a large (wide-field) single-molecule transistor (SiMoT) sensor is proposed. The system is based on an electrolyte-gated field-effect transistor whose gate is bio-functionalized with the antibody against the HIV-1 p24 capsid protein. The device exhibits a limit of detection of a single protein and a limit of quantification in the 10 molecule range. This study paves the way for a low-cost technology that can quantify, with single-molecule precision, the transition of a biological organism from being “healthy” to being “diseased” by tracking a target biomarker. This can open to the possibility of performing the earliest possible diagnosis.

scholarly journals Natural Products with Inhibitory Activity against Human Immunodeficiency Virus Type 1

2021 ◽  
Vol 2021 ◽  
pp. 1-22
Author(s):  
Maria S. Serna-Arbeláez ◽  
Laura Florez-Sampedro ◽  
Lina P. Orozco ◽  
Katherin Ramírez ◽  
Elkin Galeano ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Natural Products ◽  
Therapeutic Potential ◽  
Low Cost ◽  
Antiviral Agent ◽  
Complementary Therapy ◽  
Antiretroviral Drugs ◽  
Immunodeficiency Virus ◽  
Anti Hiv ◽  
Hiv 1

Infections caused by human immunodeficiency virus (HIV) are considered one of the main public health problems worldwide. Antiretroviral therapy (ART) is the current modality of treatment for HIV-1 infection. It comprises the combined use of several drugs and can decrease the viral load and increase the CD4+ T cell count in patients with HIV-1 infection, thereby proving to be an effective modality. This therapy significantly decreases the rate of morbidity and mortality owing to acquired immunodeficiency syndrome (AIDS) and prolongs and improves the quality of life of infected patients. However, nonadherence to ART may increase viral resistance to antiretroviral drugs and transmission of drug-resistant strains of HIV. Therefore, it is necessary to continue research for compounds with anti-HIV-1 activity, exhibiting a potential for the development of an alternative or complementary therapy to ART with low cost and fewer side effects. Natural products and their derivatives represent an excellent option owing to their therapeutic potential against HIV. Currently, the derivatives of natural products available as anti-HIV-1 agents include zidovudine, an arabinonucleoside derivative of the Caribbean marine sponge (Tectitethya crypta), which inhibits the reverse transcriptase of the virus. This was the first antiviral agent approved for treatment of HIV infection. Additionally, bevirimat (isolated from Syzygium claviflorum) and calanolide A (isolated from Calophyllum sp.) are inhibitors of viral maturation and reverse transcription process, respectively. In the present review, we aimed to describe the wide repertoire of natural compounds exhibiting anti-HIV-1 activity that can be considered for designing new therapeutic strategies to curb the HIV pandemic.

scholarly journals Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors

RSC Advances ◽  
2019 ◽  
Vol 9 (50) ◽  
pp. 28961-28986 ◽  
Author(s):  
Xiangyi Jiang ◽  
Gaochan Wu ◽  
Waleed A. Zalloum ◽  
Megan E. Meuser ◽  
Alexej Dick ◽  
...  
Keyword(s):  
Capsid Protein ◽  
Click Reaction ◽  
Protein Inhibitors ◽  
Anti Hiv ◽  
Hiv 1

Novel phenylalanine derivatives were discovered as HIV-1 capsid protein inhibitors via “click reaction”. Most of them exhibited remarkable anti-HIV-1 activity.

Design of a Gag Pentapeptide Analogue that Binds Human Cyclophilin A More Efficiently than the Entire Capsid Protein:  New Insights for the Development of Novel Anti-HIV-1 Drugs†

2000 ◽  
Vol 43 (9) ◽  
pp. 1770-1779 ◽  
Author(s):  
Quan Li ◽  
Mireille Moutiez ◽  
Jean-Baptiste Charbonnier ◽  
Karine Vaudry ◽  
André Ménez ◽  
...  
Keyword(s):  
Capsid Protein ◽  
Cyclophilin A ◽  
Anti Hiv ◽  
Hiv 1

Anticardiolipin Antibodies Are Elevated in HIV-1 Infected Haemophiliacs but Do Not Predict for Disease Progression

1989 ◽  
Vol 61 (01) ◽  
pp. 081-085 ◽  
Author(s):  
Simon Panzer ◽  
Christoph Stain ◽  
Hubert Hartl ◽  
Robert Dudczak ◽  
Klaus Lechner
Keyword(s):  
Normal Values ◽  
Anticardiolipin Antibodies ◽  
Haemophilia A ◽  
Serum Samples ◽  
Factor Viii Concentrates ◽  
Patient Groups ◽  
Anti Hiv ◽  
Hiv 1 ◽  
Cd4 Lymphocytes

SummaryLevels of anticardiolipin antibodies (ACA) were measured in 55 patients with haemophilia A in serum samples obtained in 1983 and in 1987. Twenty-one patients were negative for anti HIV-1 antibodies in 1983 and remained negative in 1987; 34 patients had anti HIV-1 antibodies in 1983; 17 of these latter patients remained asymptomatic, whereas 17 patients developed ARC or AIDS during the 4 years follow-up. Thirteen anti HIV-1 negative patients had elevated ACA levels in 1983; subsequently, a significant decrease was observed in all these subjects (p <0.001). All anti HIV-1 positive patients had elevated ACA levels in 1983; normal values were found in 9 patients in 1987. Yet, these changes were not significant (p >0.05). ACA levels were significantly higher in HIV-1 infected patients than in those without anti HIV-1 antibodies (p <0.05). There was no difference of ACA levels between the two anti HIV-1 positive patient groups, be it in 1983 or be it in 1987 (p >0.05). There was no correlation of ACA levels with serum IgG concentrations, CD4+ lymphocytes, or the consumption of factor VIII concentrates.

Sign in / Sign up

Export Citation Format

Share Document